Cancer Trial Underreporting Blamed on Time Constraints, Investigator Relocation

Drug Industry Daily
KEYWORDS FDA / Trial
A A

Phase I cancer drug trials conducted to determine the safety and maximum dosage of a new agent are underreported in peer-reviewed journals — a trend that may delay scientific advances and harm patient care — say researchers at The University of Texas M. D. Anderson Cancer Center (ACC) in a new study recently published in the journal Cancer.

To View This Article:

Login

Subscribe To Drug Industry Daily